Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
Woelfel S, Junker D, Bergamin I, Meyer-Herbon P, Stillhard R, Graf N, Leinenkugel G, Dütschler J, König M, Kammerlander L, Häuptle R, Zwyssig S, Krieger C, Truniger S, Koller S, Metzger-Peter K, Frei N, Star Sign Study Investigators, Albrich WC, Friedrich M, Bernsmeier C, Niess JH, Korte W, Bürgi JJ, Dulovic A, Schneiderhan-Marra N, Semela D, Brand S. Woelfel S, et al. Among authors: niess jh. Vaccines (Basel). 2024 Oct 31;12(11):1241. doi: 10.3390/vaccines12111241. Vaccines (Basel). 2024. PMID: 39591144 Free PMC article.
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N; STAR SIGN Study Investigators; Albrich WC, Friedrich M, Niess JH, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Among authors: niess jh. Aliment Pharmacol Ther. 2024 Oct 29. doi: 10.1111/apt.18349. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39468971
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis.
Rubin DT, Kubassova O, Weber CR, Adsul S, Freire M, Biedermann L, Koelzer VH, Bressler B, Xiong W, Niess JH, Matter MS, Kopylov U, Barshack I, Mayer C, Magro F, Carneiro F, Maharshak N, Greenberg A, Hart S, Dehmeshki J, Peyrin-Biroulet L. Rubin DT, et al. Among authors: niess jh. Inflamm Bowel Dis. 2024 Sep 16:izae204. doi: 10.1093/ibd/izae204. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39284932
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Leinenkugel G, Graf N, Krieger C, Truniger S, Franke A, Koller S, Metzger-Peter K, Oberholzer M, Frei N, Geissler N, Schaub P, Star Sign Investigators, Albrich WC, Friedrich M, Niess JH, Schneiderhan-Marra N, Dulovic A, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Among authors: niess jh. Vaccines (Basel). 2024 Jul 15;12(7):774. doi: 10.3390/vaccines12070774. Vaccines (Basel). 2024. PMID: 39066413 Free PMC article.
[Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)].
Schmidt C, Stallmach A, Sturm A, Bachmann O, Helwig U, Koletzko S, Lynen P, Schnoy E, Dignass A, Kucharzik T, Blumenstein I; Collaborators. Schmidt C, et al. Z Gastroenterol. 2024 Apr;62(4):517-534. doi: 10.1055/a-2255-7184. Epub 2024 Apr 10. Z Gastroenterol. 2024. PMID: 38599579 Free article. German. No abstract available.
81 results